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Abstract 
α-Methylacyl-CoA racemase (AMACR; P504S) is a promising novel drug target 
for prostate and other cancers. Assaying enzyme activity is difficult due to the 
reversibility of the ‘racemisation’ reaction and the difficulties in the separating 
epimeric products; consequently few inhibitors have been described and no 
structure-activity relationship study has been performed. This paper describes 
the first structure-activity relationship study, in which a series of 23 known and 
potential rational AMACR inhibitors were evaluated. AMACR was potently 
inhibited (IC50 = 400 - 750 nM) by ibuprofenoyl-CoA and derivatives. Potency was 
positively correlated with inhibitor lipophilicity. AMACR was also inhibited by 
straight-chain and branched-chain acyl-CoA esters, with potency positively 
correlating with inhibitor lipophilicity. 2-Methyldecanoyl-CoAs were ca. 3-fold 
more potent inhibitors than decanoyl-CoA, demonstrating the importance of the 
2-methyl group for effective inhibition. Elimination substrates and compounds 
with modified acyl-CoA cores were also investigated, and shown to be potent 
inhibitors. These results are the first to demonstrate structure-activity 
relationships of rational AMACR inhibitors and that potency can be predicted by 
acyl-CoA lipophilicity. The study also demonstrates the utility of the colorimetric 
assay for thorough inhibitor characterisation. 
 
Abbreviations used: AMACR, α-methylacyl-CoA racemase; CDI, 
carbonyldiimidazole;  DAST, (Diethylamino)sulfur trifluoride; DCC, 
Dicyclohexylcarbodiimide; DMAP, (dimethylamino)pyridine; MCR, 2-methylacyl-
CoA racemase from M. tuberculosis; SAR, Structure-activity relationships; THF, 
tetrahydrofuran; TMSCl, chlorotrimethylsilane.  
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Introduction 
Branched-chain fatty acids (e.g. phytanic acid pristanic acids) are common 
components of the human diet, and derivatives of such compounds are used as 
drug molecules e.g. Ibuprofen [1, 2]. Degradation of branched-chain fatty acids 
occurs as the acyl-CoA ester, and the acyl-CoA oxidases and other enzymes 
involved in β-oxidation have an absolute requirement for S-2-methylacyl-CoAs 
[3-5]. However, R-2-methylacyl-CoAs are produced from dietary and endogenous 
fatty acids and these cannot be immediately degraded by β-oxidation. The 
enzyme α-methylacyl-CoA racemase [1, 2] (AMACR; P504S; E.C. 5.1.99.4) 
catalyses conversion of R-2-methylacyl-CoAs to a near 1:1 epimeric mixture [6, 
7] by a deprotonation / reprotonation reaction [7, 8], probably via an enolate 
intermediate [9] (this reaction is referred to as “racemization” [10]). The resulting 
S-2-methylacyl-CoAs are degraded by β-oxidation whilst the 2R epimers are 
further processed to the 2S epimers by AMACR [1, 2]. AMACR also plays a key 
role in the in vivo pharmacological activation of R-Ibuprofen to S-Ibuprofen, via 
the corresponding acyl-CoA esters [1, 2, 11]. The S-Ibuprofen resulting from this 
pathway exerts its anti-inflammatory effect by inhibiting cyclooxygenase-1 and -
2 [12]. 
AMACR protein levels are increased in prostate [13, 14] and several other 
cancers [1, 15-18]. Catalytic activity of AMACR is increased by 4 to 10-fold in 
prostate cancer cells [19, 20], with the AMACR 1A splice variant [1, 2, 21-24] 
(possessing “racemase” activity [7, 10]) showing the most significant increase in 
expression [19, 20]. Reducing AMACR 1A levels using siRNA or shRNA 
approaches [19, 25, 26] has been shown to reduce proliferation of prostate 
cancer cells via a pathway which is synergistic with the use of an androgen 
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receptor antagonist, studies which have validated AMACR 1A as a 
chemotherapeutic target. Some advanced prostate cancer cell lines revert from 
castrate-resistant (a.k.a. androgen-independent) growth to androgen-dependent 
growth upon knockdown of AMACR 1A [26]. Consequently, AMACR has 
attracted considerable interest as a prostate cancer biomarker [1, 2, 27] and drug 
target [25, 28-31]. However, the lack of a convenient assay to measure AMACR 
activity [32, 33] has severely hampered the development of AMACR inhibitors as 
new chemotherapeutic drugs against cancers that over-express AMACR, and 
consequently only a few rationally designed inhibitors of AMACR [28-30, 34] or 
MCR [31, 35] (M. tuberculosis homologue) have been reported. No systematic 
study of AMACR inhibitor SAR has been undertaken [32, 33].  
Recently, we reported a versatile continuous assay for AMACR based on 
the utilisation of our novel substrate 1 that can eliminate 2,4-dinitrophenolate 2, 
which can be monitored by absorbance at 354 nm, and unsaturated product 3 
(Scheme 1). This new assay [32] was used to examine the potency of two known 
acyl-CoA inhibitors (N-dodecyl-N-methylcarbamoyl-CoA 4 [29] and ibuprofenoyl-
CoA 5 [6]; Figure 1) and selected known non-specific protein modification agents 
[25]. This paper reports the first systematic examination of SAR for rationally 
designed acyl-CoA inhibitors of AMACR. Compounds investigated (Figure 1) 
include those with aromatic side-chains, (5 - 11); Straight-chain acyl-CoA esters 
(12 – 17); Branched-chain substrates (18 – 21) and product 22. Analogues of 
known inhibitors with modified 2-methylacyl-CoA moieties (4, 23 - 26) were also 
examined. The results reveal a correlation between potency and lipophilicity of 
the inhibitors, consistent with observations on MCR inhibitors [35], the 
homologous enzyme from M. tuberculosis. 
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Results and discussion 
AMACR is a promising novel cancer drug target, but therapeutic development 
in this field has been slow due to the lack of a robust enzyme assay. Thus, the 
majority of studies reporting AMACR inhibitors have largely focussed on 
rationally designed drugs [28-30, 32, 33]. In most cases, only one or a few 
examples of each inhibitor type has been evaluated, and no systematic SAR 
study has been performed. Initial SAR studies have been carried out on 
reversible [31] and irreversible [35] inhibitors of MCR (the M. tuberculosis 
homologue). In addition, different research groups have used different assays 
during their studies, making it difficult to compare results. In this study, the SAR 
of rational AMACR inhibitors were explored using a series of acyl-CoA esters 
(Figure 1). These included compounds previously tested as substrates (6 – 11 
[6, 11]; 12 – 17 [36]; 18 – 20, 22 [7, 10]). Most of these compounds have not 
been tested as inhibitors with the exception of 5 [28, 32, 37, 38] and 13, 15-17 
(which were previously reported to be inactive [37, 38]). Compound 21 was 
included as an epimer of 20, and has not been previously reported as a substrate 
or inhibitor (although the 3-fluoro-2-methyltetradecanoyl-CoA analogues are 
potent inhibitors [28]). Compound 24 is a synthetic intermediate to 25, and has 
not been previously tested as a substrate or inhibitor. Compounds 22, 25 and 26 
are intermediates in the subsequent β-oxidation pathway [39], and have not been 
previously tested as substrates or inhibitors. Analogues of compounds 23, and 
25 with different side-chains have been previously tested as inhibitors of AMACR 
or MCR [9, 30]. Compound 4 was previously reported as the most potent AMACR 
inhibitor [29, 32], and is included as an acyl-CoA core analogue. 
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Chemical synthesis of acyl-CoA inhibitors 
(2S,3S)-3-Fluoro-2-methyldecanoyl-CoA 21 was synthesised by an analogous 
route to (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 20 [10, 28], using an Evans’ 
auxiliary strategy (Scheme 2). Aldol-like reaction of deprotonated 27 with octanal 
gave the (2S,3R)-3-hydroxy-2-methyl intermediate 28. From here, alcohol 28 was 
activated and replaced with fluoride with inversion of configuration, using DAST 
to give 3-fluoro-2-methyl derivative 29. The reaction is thought to go with 
inversion of stereochemical configuration (by analogy with the work of Carnell et 
al. [28]). Removal of the Evans’ auxiliary from intermediate 29 provided the 
carboxylic acid 30 under mild conditions that involved in situ generation of lithium 
hydroperoxide. Intermediate 30 was subsequently converted to the CoA thioester 
21 using the standard synthetic method with N,N’-carbonyldiimidazole [6, 10, 11, 
32, 33, 40]. This compound was stable in solution in the absence of AMACR, 
showing that the relative geometry of the α-proton and fluorine atom was syn- 
(anti- epimers rapidly eliminate fluoride, presumably by an E2 mechanism [10]). 
2-Methylenedecanoyl-CoA 23 was synthesised by an adaptation of the 
method reported by Morgenroth et al. [30] (Scheme 3). Meldrum’s acid 33 was 
acylated with octanoic acid 32 using DCC activation; the intermediate ketone was 
reduced to the octyl-Meldrum’s acid 31 with sodium triacetoxyborohydride 
generated in situ. Subsequent reaction of 31 with Eschenmoser’s salt gave the 
2-methylene ester 34. Base-hydrolysis furnished the 2-methylene acid 35, which 
was coupled with CoA-SH by a mixed anhydride approach to give 2-
methylenedecanoyl-CoA 23. 
2-Methyl-3-oxodecanoyl-CoA 25 was synthesised by the method of Reen et 
al. [41] from 36 (Scheme 4). The ketone in 37 was protected as the cyclic acetal 
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36. Hydrolysis of the ester group in 36 gave the corresponding acid 38, which 
was then coupled with CoA [6, 10, 11, 32, 33, 40] to give 24. Acidolysis of the 
acetal protection provided 25. 
2S,3R-3-Hydroxy-2-methyldecanoyl-CoA 26 was synthesised (Scheme 5) 
from the acyl-Evan’s auxiliary 28 (Scheme 2, vide supra) by hydrolysis with 
lithium hydroperoxide to give acid 39, which was converted to the CoA ester 26 
using the standard procedure [6, 10, 11, 32, 33, 40]. 
 
Evaluation of inhibitors 
The selected AMACR inhibitors were evaluated using the colorimetric assay [32]. 
Incubation of active human AMACR 1A with substrate 1 results in production of 
2,4-dinitrophenolate 2 and unsaturated product 3 (Scheme 1). Hence, the 
potency of inhibitors can be determined based on measuring the  absorbance of 
2 at 354 nm. Inhibitory potency was assessed using dose-response curves to 
determine IC50 values (Figure 1). 
As expected, ibuprofenoyl-CoA 5 and its derivatives 6 – 9 were inhibitors of 
the enzyme, with most having IC50 values of  ca. 500 nM (Figure 1). Variation of 
the structure of the side-chain in these inhibitors appeared to make little 
difference to inhibitory activity (as judged by IC50 values), although fenoprofenoyl-
CoA 6 appeared to be slightly more potent than the other examples and 
naproxenoyl-CoA 9 appeared to be slightly less so. All these compounds are 
known substrates of AMACR [6] and are predicted to behave as competitive 
inhibitors. Ibuprofenoyl-CoA 5 has been previously confirmed to be a competitive 
inhibitor of AMACR, with Ki = 60 nM [32], consistent with observations of other 
workers on the human and rat enzymes [28, 37, 38]. The mandelic acid 
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derivatives R- and S-2-hydroxy-2-phenylacetyl-CoA 10 and 11 were also modest 
inhibitors (Figure 1), binding approximately ten times less strongly than 
compounds 5 – 9. Compounds 10 and 11 are not substrates of AMACR, since 
enzyme catalysed α-proton exchange does not occur [11]. This result with 10 and 
11 also demonstrates that inhibitors can possess a 2-hydroxy- group in addition 
to the previously reported 2-trifluoromethyl- [28] and 2-chloro- [29] groups in 
place of the 2-methyl group. A wide range of aromatic inhibitor side-chains can 
therefore be accomodated by the enzyme, consistent with predictions made 
based on the MCR crystal structures [8] and biochemical data [6, 11].  
Acyl-CoA esters 12 - 17, possessing alkyl side-chains were also assessed as 
inhibitors (Figure 1). The potency of inhibition for acyl-CoA esters with side-
chains of four carbons or fewer (15 – 17) is very weak, with low levels of inhibition 
(15-30%) observed even at very high inhibitor concentrations (100 µM). Inhibition 
increased as alkyl chain-length increased. This behaviour is consistent with that 
of straight-chain acyl-CoA esters acting as substrates [36], where increased 
levels of α-proton exchange are observed with increasing chain length. Our 
results showing inhibition of AMACR  by straight-chain acyl-CoA esters contrasts 
with the early observations of Schmitz et al., who reported that these compounds 
were not inhibitors of the native human and rat enzymes [37, 38].  
Inclusion of a 2-methyl group on the inhibitor increased potency by about 3-
fold (compounds 18 and 19 compared to 12), again consistent with the finding 
that 2-methylacyl-CoA esters are much more efficient substrates than their 
straight-chain equivalents [36]. R-2-Methyldecanoyl-CoA 18 appeared to be a 
slightly more potent inhibitor than S-2-methyldecanoyl-CoA 19, and this probably 
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reflects the physiological role of AMACR in the conversion of R-2-methylacyl-
CoAs to their S-2-methylacyl-CoA epimers [1, 2].  
2-Methyldecanoyl-CoA derivatives with more acidic α-protons are better 
inhibitors than their parent compounds (Figure 1). R,R-3-Fluoro-2-
methyldecanoyl-CoA 20 was about 5-fold more potent than was R-2-
methyldecanoyl-CoA 18. A similar trend was observed with S,S-3-fluoro-2-
methyldecanoyl-CoA 21 and S-2-methyldecanoyl-CoA 19, although both of these 
compounds were slightly less potent than their R-epimers. The product of the 
reaction, E-2-methyldec-2-enoyl-CoA 22, is also a potent inhibitor. It is therefore 
difficult to determine if the observed IC50 values for 20 or 21 reflect the conversion 
of these substrates [10], product inhibition by 22 or both. These observations 
contrast with early studies [37, 38], which suggest that 22 was not an inhibitor of 
AMACR. 
2-Methyl-3-oxodecanoyl-CoA 25 was also a good inhibitor of AMACR. The α-
proton of this compound is relatively acidic and 25 undergoes rapid non-
enzymatic α-proton exchange with solvent via an enolate intermediate. It was 
therefore not possible to analyse the influence of 2-methyl group stereochemical 
configuration. The precursor 24 was a much poorer inhibitor than 25, presumably 
due to reduced acidity of the α-proton. It is also possible that the additional steric 
bulk at carbon-3 contributes to the lower potency of 24 compared to 25, as the 5-
membered ring of 24 will be twisted out of plane relative to the aliphatic side-
chain. However, AMACR is known to be able to accept substrates with diverse 
side-chain structures [6, 28, 36-38] and it is notable that ibuprofenoyl-CoA 5 and 
derivatives 6 - 9 (which have aromatic rings at the equivalent position) are potent 
inhibitors (Figure 1).    
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2S,3R-3-Hydroxy-2-methyldecanoyl-CoA 26 is also a relatively potent 
inhibitor. Incubation of 26 with active AMACR did not result in an elimination 
reaction, as judged by the lack of a peak at δ 1.75 ppm [10] from the 2-methyl 
group of the anticipated product 22 (Figure 2), probably because hydroxide is a 
relatively poor leaving group (water pKa = ~7), compared to fluoride (HF pKa = 
3.2) [42]. Similarly, 1H NMR analysis of the reaction products showed that 26 did 
not undergo α-proton exchange, and hence 26 is not a substrate of AMACR. It is 
notable that 22, 24 and 26 are intermediates in the branched-chain acyl-CoA β-
oxidation pathway. One may speculate that these compounds could provide 
some regulation of AMACR by negative feedback control, and hence control entry 
of R-2-methylacyl-CoA esters into the β-oxidation pathway. Whether or not this 
is physiologically significant will depend on rates of flux through the β-oxidation 
pathway and whether intermediates 22, 24 and 26 are sequestered away from 
AMACR.  
Acyl-CoAs which mimic the planar enolate intermediate are good inhibitors of 
AMACR (Figure 1). E-2-Methyldec-2-enoyl-CoA 22 and 2-methylenedecanoyl-
CoA 23 bind strongly due to having a planar sp2-hybridized α-carbon. This result 
is consistent with a previous study in which 2-methyleneacyl-CoAs were shown 
to be good competitive inhibitors [2, 30]. The enolate analogue N-dodecyl-N-
methylcarbamoyl-CoA 4 is the best rationally designed inhibitor (IC50 = 0.4 nM) 
reported to date [29, 32]. Inhibition by 4 is ca. 2000 more potent than by 18 and 
19 (Figure 1). This high potency of 4 appears to largely result from the mimicking 
of the enolate intermediate by the carbamoyl moiety. It is also notable that the 
determined IC50 value for 4 in this study (0.4 nM) is significantly lower than that 
previously determined by Carnell et al. (98 nM), when assayed against HEK-
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derived human AMACR using ibuprofenoyl-CoA 5 as substrate [29]. It appears 
that the colorimetric assay consistently determines higher levels of compound 
potency than other assays (e.g. Ki = 60 nM [32] vs. 56 µM [28, 38] for an 
ibuprofenoyl-CoA epimeric mixture) The reasons for this discrepancy is not 
entirely clear, but higher apparent potency may be a consequence of using a 
substrate undergoing an irreversible reaction to measure activity (and hence 
avoiding the error introduced by the presence of the reverse reaction). 
Alternatively, this may be related to the extent of substrate or inhibitor micelle 
formation under the different assay conditions.  
The determined IC50 value (0.4 nM) is around half the calculated ‘active’ 
enzyme concentration in the assay [32] (based on comparison of kcat/Km values 
for the E. coli and HEK cell derived enzymes [29]), and hence 4 could be 
behaving as a tight-binding inhibitor. Compound 4 behaves as a rapidly reversible 
competitive inhibitor of AMACR, with a Hill coefficient of ~0.7 [32]. These 
observations are consistent with the zone A inhibitor behaviour described by 
Straus and Goldstein [43, 44], i.e. the enzyme active site concentration is <0.1  
the apparent Ki value (0.65 nM [32]). This rapidly reversible inhibition is 
significantly different behaviour to that observed for similar compounds (gem- 
carbamoyl inhibitors and N-decyl-carbamoyl-CoA) with the highly homologous 
bacterial enzyme MCR, where  time-dependent inactivation was observed [35]. 
The reasons for this difference in behaviour are not entirely obvious. 
 
Influence of the side-chain lipophilicity on inhibitor potency 
AMACR is able to catalyse the ‘racemisation’ of substrates with structurally 
diverse side-chains [1, 2]. The accommodation of these diverse structures is 
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thought to be a result of non-specific binding of the side-chain by hydrophobic 
interactions to a methionine-rich surface [8]. Consistent with this, the MCR gem- 
[31] and gem- carbamate [35] inhibitors show increased potency for compounds 
with more hydrophobic alkyl side-chains. Consequently, we were interested to 
investigate whether inhibitor potency was related to the lipophilicity of the inhibitor 
side-chain. A plot of determined IC50 values vs. calculated LogP values for the 
acyl-CoA inhibitor (Figure 3) showed that high LogP values tend to produce low 
IC50 values. Systematic trends were observed within those compounds 
containing aromatic side-chains (5 - 11), with potency positively correlating with 
lipophilicity. It is also notable that 10 and 11, possessing a single phenyl group 
side-chain are significantly less potent than compounds containing more lipophilic 
side-chains. This consistent behaviour tends to suggest that side-chain 
lipophilicity is driving potency, with the 2-hydroxy group of 10 and 11 making a 
smaller contribution. Systematic trends were also observed for inhibitors 
possessing alkyl side-chains (12 - 17), showing that lipophilicity is also an 
important determinant of potency for this series.  
The enolate analogue 4 has a potency increased by ~875-fold compared to 
that predicted based on LogP values (measured IC50 = ~0.4 nM vs. ~350 nM 
predicted for miLogP = 2.61) (Supplementary Information, Figure S1), showing 
the effectiveness of the carbamate moiety in promoting inhibition. Acyl-CoA 
esters do not comply with Lipinski guidelines and hence AMACR inhibitors are 
delivered as their acid pro-drugs [28, 30, 32, 34] which are converted to the acyl-
CoA in vivo. Although 4 has very high potency, delivery as the pro-drug will be 
challenging because carbamates readily decarboxylate to the corresponding 
amine. 
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Conclusions 
This is the first systematic SAR study of rationally designed AMACR inhibitors. 
The study illustrates that extremely diverse side-chain structures which can be 
accommodated. A minimal level of side-chain lipophilicity is required for efficient 
binding. For compounds with aromatic side-chains, a single aromatic ring results 
in modest inhibition whilst more than one aromatic ring or an aromatic ring with 
alkyl substituents results in much more potent inhibition. Similarly, a minimum of 
a 6-carbon alkyl chain appears to be required for reasonably efficient inhibitor 
binding, with increased potency resulting from addition of further –CH2– groups. 
Our results allow investigation of the contribution to potency made by the 
individual structural elements of these inhibitors. 
AMACR has attracted much attention as both a novel drug target and cancer 
marker since its involvement in prostate cancer was reported [14, 19]. However, 
exploitation of this discovery has been extremely limited, largely due to the 
absence of a suitable assay with which to test inhibitor potency [33]. This study 
shows that our novel colorimetric assay [32] allows quick and accurate 
measurement of drug potency and detailed kinetic characterisation of inhibitors. 
The systematic investigation of novel inhibitor SAR and therapeutic development 
is now possible. 
 
Materials and methods 
Sources of materials 
Chemicals were purchased from the Sigma-Aldrich Chemical Co. or Fisher 
Scientific Ltd., unless otherwise stated and were used without further purification. 
Reduced coenzyme A, tri-lithium salt was purchased from Calbiochem. Acyl-CoA 
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esters 4 [33], 5-9 [6], 10 and 11 [11] were synthesised as previously described. 
Acyl-CoA esters 12 – 17 were purchased from Larodan Lipids. Substrates 18-20 
and product 22 were synthesised as described [7, 10]. Human recombinant 
AMACR 1A was expressed and purified and substrate 1 synthesised as 
previously described [32]. 
 
General experimental procedures 
Thin layer chromatography was performed on Merck silica aluminium plates 60 
(F254) and UV light, potassium permanganate or phosphomolybdic acid were 
used for visualisation. Column chromatography was performed using Fisher silica 
gel (particle size 35-70 micron). Purifications of acyl-CoA esters were performed 
by solid phase extraction using Oasis HLB 6cc (200 mg) extraction cartridges. 
Phosphate buffer was prepared from monobasic sodium phosphate and NaOH 
at the required proportions. Citric acid buffer was prepared from citric acid and 
NaOH at the required proportion for 0.8 M pH 4.0 buffer. The pH of aqueous 
solutions was measured using a Corning 240 pH meter and Corning general 
purpose combination electrode. The pH meter was calibrated using Fisher 
Chemicals standard buffer solutions (pH 4.0 - phthalate, 7.0 - phosphate, and 
10.0 - borate) at either pH 7.0 and 10.0 or 7.0 and 4.0. Calibration and 
measurements were carried out at ambient room temperature. IR spectra were 
recorded on Perkin-Elmer RXI FTIR spectrometer instrument. NMR spectra were 
recorded on Bruker Avance III 400.04 MHz or 500.13 MHz spectrometers in D2O, 
(CD3)2SO or CDCl3 and the solvent was used as an internal standard. Shifts are 
given in ppm and J values reported to  0.1 Hz. Multiplicities of NMR signals are 
described as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Stock 
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concentrations of acyl-CoA esters for assays were determined using 1H NMR. 
Mass spectra were recorded by ESI TOF. High resolution mass spectra were 
recorded in ES mode. Melting points were determined using a Gallenkamp 
melting point apparatus and are uncorrected. Syntheses were carried out at 
ambient temperature, unless otherwise specified. Solutions in organic solvents 
were dried over anhydrous MgSO4 and the solvents were evaporated under 
reduced pressure. Aqueous solutions for biological experiments were prepared 
in Nanopure water of 18.2 MΩ.cm-1 quality and were pH-adjusted with aq. HCl or 
NaOH. 
 
(4S)-4-Benzyl-3-[(2S,3R)-3-hydroxy-2-methyldecanoyl]-1,3-oxazolidin-2-
one (28) 
(S)-(+)-4-Benzyl-3-propanoyl-2-oxazolidinone 27 (3.0 g, 12.9 mmol) in CH2Cl2 
(30.0 mL) was cooled to -78°C. Dibutylboron triflate (1.0 M in CH2Cl2, 13.0 mL, 
12.9 mmol) and Pri2NEt (2.3 mL, 12.9 mmol) were added and the mixture was 
stirred for 30 min before octanal (1.4 mL, 9.2 mmol) in CH2Cl2 (9.0 mL) was added 
dropwise. The mixture was stirred at -78°C for further 30 min and then at room 
temperature for 2 h. aq. Sodium phosphate buffer at pH 7.0 (100 mM, 100 mL) 
was added slowly to the reaction mixture. The organic layer was washed [aq. HCl 
(1.0 M), aq. NaHCO3 (saturated), brine] and dried. Column chromatography 
(Petroleum ether / EtOAc 10:1  6:1) gave 28 (2.53 g, 76%) as a colourless oil. 
[α]D21 +51.4 (c 0.74 in CHCl3); IR max 3517 (OH), 1780 (C=O), 1692 (C=O) cm-1; 
1H NMR (500.13 MHz; CDCl3) δH 7.26-7.07 (5 H, m, Ar-H), 4.65-4.55 (1 H, m, 4-
H), 4.16-4.05 (2 H, m, 5-H), 3.89-3.80 (1 H, m, 3’-H), 3.68 (1 H, qd J = 7.0, 3.0 
Hz, 2’-H), 3.14 (1 H, dd, J = 13.0, 3.0 Hz, CHHAr), 2.92 (1 H, s, OH), 2.70 (1 H, 
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dd, J = 13.0, 9.0 Hz, CHHAr), 1.50-1.10 (15 H, m, 6 × CH2 and CH3CH), 0.79 (3 
H, t, J = 6.5 Hz, 10’-H3); 13C NMR (125.77 MHz, CDCl3) δC177.23 (1’-C), 152.87 
(2-C), 134.92 (Ar-C), 129.24 (Ar-C), 128.73 (Ar-C), 127.18 (Ar-C), 71.35 (3’-C), 
65.96 (5-C), 54.91 (4-C), 42.02 (2’-C), 37.53 (CHHAr), 33.77 (CH2), 31.62 (CH2), 
29.35 (CH2), 29.05 (CH2), 25.84 (CH2), 22.45 (CH2), 13.90 (CH3CH), 10.31 (10’-
C); ESI-MS m/z 384.2134 [M + Na]+ (C21H31NNaO4 requires 384.2151). 
 
(4S)-4-Benzyl-3-[(2R,3S)-3-fluoro-2-methyldecanoyl]-1,3-oxazolidin-2-one 
(29) 
(Diethylamino)sulfur trifluoride (0.5 mL, 3.9 mmol) in CH2Cl2 (10.0 mL) was added 
dropwise to 28 (1.4 g, 3.9 mmol) in CH2Cl2 (20.0 mL) at -78C and the mixture 
was stirred for 2 h at this temperature. It was stirred for a further 2 h at room 
temperature, before being quenched with water (50 mL). The organic layer was 
washed (saturated aq. NaHCO3, brine). Column chromatography (Petroleum 
ether / EtOAc 30:1 gave 29 (490 mg, 35%) as a colourless oil. [α]D21 +49.2 (c 0.63 
in CHCl3); IR max 1782 (C=O), 1700 (C=O) cm-1; 1H NMR (500.13 MHz; CDCl3) 
δH 7.27-7.06 (5 H, m, Ar-H), 4.76-4.57 (2 H, m, 4-H and 3’-H), 4.15-3.96 (3 H, m, 
5-H and 2’-H), 3.17 (1 H, dd, J = 13.5, 3.5 Hz, CHHAr), 2.72 (1 H, dd, J = 13.5, 
9.5 Hz, CHHAr), 1.70-1.14 (12 H, m, 6 × CH2), 1.10 (3 H, d, J = 7.0 Hz, CH3CH), 
0.80 (3 H, t, J = 6.5 Hz, 10’-H3); 13C NMR (125.77 MHz, CDCl3) δC 174.37 (d, J = 
2.8 Hz, 1’-C), 153.12 (2-C), 135.25 (Ar-C), 129.47 (Ar-C), 128.93 (Ar-C), 127.37 
(Ar-C), 94.89 (d, J = 169.8 Hz, 3’-C), 66.19 (5-C), 55.38 (4-C), 42.03 (d, J = 20.9 
Hz, 2’-C), 37.85 (CHHAr), 32.04 (d, J = 20.9 Hz, 4’-CH2), 31.79 (CH2), 29.37 
(CH2), 29.16 (CH2), 24.57 (d, J = 2.8 Hz, 5’-CH2), 22.64 (CH2), 14.10 (10’-C) and 
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13.62 (d, J = 8.5 Hz, 2’-CH3); δF (470 MHz, CDCl3) -179.67; ESI-MS m/z 386.2126 
[M + Na]+ (C21H30FNNaO3 requires 386.2107). 
 
(2R,3S)-3-Fluoro-2-methyldecanoic acid (30) 
H2O2 aq. [30% (w/w), 0.7 mL] and LiOH (62 mg, 2.6 mmol) were added to 29 (472 
mg, 1.3 mmol) in THF (14 mL) at 0C. The mixture was stirred at ambient 
temperature for 20 h before being quenched with sat. aq. sodium sulfite (14 mL). 
The THF was evaporated and the mixture was acidified with aq. HCl (1.0 M) to 
pH 1.0 and extracted with CH2Cl2 (100 mL). The organic phase was washed with 
water (75 mL) and brine (75 mL). The combined organic layers were dried and 
the solvent was evaporated. Column chromatography (petroleum ether / EtOAc 
5:1) gave 30 (245 mg, 92%) as a white solid. mp 64-65°C; [α]D21 -7.8 (c 0.51 in 
CHCl3); IR max 2925 (OH), 1693 (C=O) cm-1; 1H NMR (400.04 MHz; CDCl3) δH 
10.89 (1 H, br s, OH), 4.58-4.50 (1 H, m, 3-H), 2.58-2.52 (1 H, m, 2-H), 1.75-1.23 
(12 H, m, 6 × CH2), 1.20 (3 H, d, J = 7.2 Hz, CH3CH), 0.88 (3 H, t, J = 6.8 Hz, 10-
H3); 13C NMR (100.60 MHz, CDCl3) δC 180.02 (d, J = 5.6 Hz, C=O), 94.28 (d, J = 
172.2 Hz, 3-C), 44.37 (d, J = 22.0 Hz, 2-C), 31.74 (d, J = 21.1 Hz, 4-CH2), 31.74 
(CH2), 29.30 (CH2), 29.12 (CH2), 24.82 (d, J = 3.0 Hz, 5-CH2), 22.61 (CH2), 14.05 
(10-C) and 12.56 (d, J = 6.6 Hz, 2-CH3); 19F NMR (470 MHz, CDCl3) δF -181.94; 
ESI-MS m/z 203.1449 [M - H]- (C11H20FO2 requires 203.1447). 
 
(2S,3S)-3-Fluoro-2-methyldecanoyl-CoA (21) 
Carbonyldiimidazole (48 mg, 0.29 mmol) was added to (2R,3S)-3-fluoro-2-
methyldecanoic acid 30 (30.0 mg, 0.15 mmol) in anhydrous CH2Cl2 (2 mL) and 
the mixture was stirred at ambient temperature for 1 h. CH2Cl2 (3 mL) was added 
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to the mixture, which was with water (5 × 2 mL) and brine (2 mL) and dried. The 
solvent was evaporated to obtain the crude acyl-imidazole intermediate. Aq. 
NaHCO3 (1.0 mL, 0.10 M) and tri-lithium CoA-SH (17.0 mg, 0.02 mmol) was 
added to the crude intermediate in THF (1.0 mL) and the mixture was stirred at 
ambient temperature for 18 h. The THF was evaporated and the residue was 
acidified to ca. pH 3 by addition of aq. HCl (1.0 M HCl). The mixture was diluted 
with water (2.0 mL) and washed with EtOAc (3 × 3 mL). The crude aqueous 
solution was freeze-dried and purified with solid-phase extraction to give 21 (13.6 
mg) as a white solid. 1H NMR (500 MHz, D2O) δH 8.63 (1 H, s, adenosine CH), 
8.38 (1 H, s, adenosine CH), 6.16 (1 H, d, J = 6.0 Hz, adenosine CH), 4.30-4.10 
(2 H, m, adenosine CH2), 3.97 (1 H, s, adenosine CH), 3.85-3.72 (1 H, m, 
CoA(OCHH)), 3.58-3.47 (1 H, m, CoA(OCHH)), 3.39 (2 H, t, J = 6.5 Hz, 
CoA(CH2)), 3.29 (2 H, t, J = 6.0 Hz, CoA(CH2)), 3.08-2.90 (3 H, m, CoA(SCH2) 
and CHCH3), 2.36 (2 H, t, J = 6.5 Hz, CoA(CH2)), 1.68-1.44 (2 H, m, CHH and 
CHH), 1.39-1.12 (10 H, m, 5 × CH2), 1.07 (3 H, d, J = 7.0 Hz, CHCH3), 0.87 (3 H, 
s, CoA(CH3)), 0.81-0.70 (6 H, m, CH2CH3 and CoA(CH3)); 19F NMR (470 MHz) 
δF -181.11; ESI-MS m/z 475.6220  [M – 2 H]2- (C32H53FN7O17P3S requires 
475.6208). 
 
2,2-Dimethyl-5-octyl-1,3-dioxane-4,6-dione (31) 
4-Dimethylaminopyridine (1.296 g, 10.6 mmol), N,N’-dicyclohexylcarbodiimide 
(1.0 M in CH2Cl2, 11.1 mL, 11.1 mmol) and octanoic acid 32 (1.6 mL, 10 mmol, 
1.0 eq.) were added to Meldrum’s acid 33 (1.455 g, 10.1 mmol) in dry CH2Cl2 
(100 mL). The mixture was stirred at ambient temperature for 40 h. The 
precipitate was removed by filtration and the filtrate was washed with aq. KHSO4 
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(1.0 M, twice), water and brine, then dried. AcOH (6.0 mL) was added to the 
filtrate. To this solution, NaBH4 (802 mg, 21.2 mmol) was added in portions during 
1 h and the mixture was stirred for an additional 20 h. The evaporation residue 
was dissolved in Et2O (100 mL) and washed with water (twice) and brine (100 
mL). Drying and evaporation gave 31 (2.30 g, 89 %) as a white solid: mp. 64-
65°C (lit. [45] mp. 65-67C); 1H NMR (400.04 MHz, CDCl3): δH 3.49 (1 H, t, J = 
4.9 Hz, dioxane 5-H), 2.14-2.04 (m, 2 H, octyl 1-H2), 1.77 (3 H, s, 2-CH3), 1.75 (3 
H, s, 2-CH3), 1.48-1.38 (2 H, m, octyl 3-H2), 1.37-1.19 (10 H, m, octyl 4,5,6,7-H8), 
0.86 (3 H, t, J = 7.0 Hz, octyl 8-H3); 13C NMR (125.77 MHz, CDCl3): δC 165.6, 
104.7, 46.1, 31.8, 29.5, 29.2, 29.1, 28.4, 26.9, 26.6, 26.5, 22.6, 14.1; IR (KBr disc) 
nmax 1752 (C=O) cm-1; ESI-MS m/z 279.1577 [M + Na]+ C14H24NaO4 requires 
279.1572; 257.1732 [M + H]+ (C14H25O4 requires 257.1753). 
 
Methyl 2-methylenedecanoate (34) 
Compound 31 (2.10 g, 8.19 mmol) was dissolved in anhydrous MeOH (26 mL). 
Eschenmoser's salt (3.79 g, 20.5 mmol, 2.5 eq.) was added and the mixture was 
heated at reflux for 40 h. The solvent was evaporated. The residue, in Et2O (100 
mL), was washed with aq. KHSO4 (1.0 M), water and brine and was dried. 
Evaporation and column chromatography (petroleum ether / EtOAc 10:1) gave 
34 (1.10 g, 74 %) as a colourless oil (lit.[46] oil): IR (neat) nmax 1725 (C=O) cm-1; 
1H NMR (400.04 MHz, CDCl3): δH 6.12-6.10 (1 H, m, =CHH), 5.52-5.49 (1 H, m, 
=CHH), 3.73 (3 H, s, OCH3), 2.31-2.23 (2 H, m, 3-H2), 1.49-1.37 (2 H, m, 4-H2), 
1.34-1.19 (10 H, m, 5,6,7,8,9-H10), 0.86 (3 H, t, J = 7.1 Hz, 10-H3); 13C NMR 
(125.77 MHz, CDCl3): δC 167.8, 140.8, 124.4, 51.7 (two carbons), 31.8, 29.3, 
29.2, 29.2, 28.3, 22.6, 14.0. 
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2-Methylenedecanoic acid (35) 
Methyl ester 34 (870 mg, 4.39 mmol) was stirred at 50 °C for 2 h with aq. NaOH 
(1.0 M, 15 mL, 15 mmol) in EtOH (57 mL), then cooled to ambient temperature 
and acidified to pH ca. 3. The volatile solvents were evaporated. The residue, in 
Et2O (50 mL), was washed with water (twice) and brine and was dried. 
Evaporation and column chromatography (petroleum ether / EtOAc 3:1) gave 35 
(650 mg, 80 %) as a colourless oil (lit. [47] oil): IR (neat) nmax 1696 (C=O) cm-1;1H 
NMR (400.04 MHz, CDCl3): δH 12.05 (1 H, br s), 6.34-6.23 (1 H, m, =CHH), 5.70-
5.59 (1 H, m, =CHH), 2.32-2.25 (2 H, m, 3-H2), 1.54-1.40 (2 H, m, 4-H2), 1.36-
1.19 (10 H, m, 5,6,7,8,9-H10), 0.87 (3 H, t, J = 7.0 Hz, 10-H3); 13C NMR (125.77 
MHz, CDCl3): δC 173.0, 140.2, 126.9, 31.8, 31.4, 29.3, 29.2, 29.2, 28.3, 22.6, 
14.1; ESI-MS m/z 207.1349 [M + Na]+ C11H20NaO2 requires 207.1361); 183.1396 
[M]- (C11H19O2 requires 183.1385).  
 
2-Methylenedecanoyl-CoA (23) 
Ethyl chloroformate (17 µL, 19 mg, 0.18 mmol) was added to 35 (33 mg, 0.18 
mmol) and NEt3 (25 µL, 18 mg, 0.18 mmol) in anhydrous THF (2.0 mL) and the 
mixture was stirred at ambient temperature for 1 h. CoA-SH tri-lithium salt [(28 
mg, 0.04 mmol) in aq. KHCO3 (2.5%), 2.0 mL] was added and the mixture was 
stirred at ambient temperature for 16 h. The mixture was acidified to pH ca. 3 with 
aq. HCl (1.0 M) and the THF was evaporated. The solution was washed with 
EtOAc (5 × 3 mL) and the crude product was purified by SPE to give 23 (7.0 mg) 
as a colourless solid: 1H NMR (500.13 MHz, D2O): δH 8.47 (1 H, s), 8.16 (1 H, s), 
6.07 (1 H, d, J = 7.0 Hz), 5.96 (1 H, s), 5.55 (1 H, s), 4.19-4.11 (1 H, m), 3.75 (1 
H, dd, J = 9.8, 5.1 Hz), 3.46 (1 H, dd, J = 9.8, 4.8 Hz), 3.36 (2 H, t, J = 6.5 Hz), 
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3.31-3.25 (2 H, m), 2.95 (2 H, t, J = 6.2 Hz), 2.33 (2 H, t, J = 6.6 Hz), 2.16 (2 H, 
t, J = 7.3 Hz), 1.30-1.22 (2 H, m), 1.18-1.06 (10 H, m), 0.79 (3 H, s), 0.75 (3 H, t, 
J = 6.8 Hz), 0.65 (3 H, s); ESI-MS m/z 465.6152 [M – 2 H]2- (C32H52N7O17P3S 
requires 465.6177). 
 
Methyl 2-(2-heptyl-1,3-dioxolan-2-yl)propanoate (36) 
Ethane-1,2-diol (5.27 g, 84.8 mmol) was added to 37 (606 mg, 2.83 mmol) in dry 
CH2Cl2 (26 mL). Me3SiCl (1.84 g, 2.15 mL, 17.0 mmol) was added and the 
mixture was stirred at ambient temperature for 3 d. Further ethane-1,2-diol (5.27 
g) and Me3SiCl (1.84 g) were added and the mixture was stirred for a further 3 d. 
Water (25 mL) was added and the mixture was extracted with CH2Cl2  (3 × 20 
mL). The combined organic layers were washed with water (5 × 70 mL) and brine 
(70 mL) and were dried. Evaporation and column chromatography (petroleum 
ether / EtOAc 10:1) gave 36 (600 mg, 82%) as a colourless oil: IR (neat) nmax 
1740 (C=O) cm-1; 1H NMR (400.04 MHz, CDCl3) δH 4.04-3.90 (4 H, m, 
OCH2CH2O), 3.67 (3 H, s, OCH3), 2.83 (1 H, q, J = 7.2 Hz, CHCH3), 1.81-1.62 (2 
H, m, heptyl 1-H2), 1.42-1.20 (10 H, m, heptyl 2,3,4,5,6-H10), 1.18 (3 H, d, J = 7.2 
Hz, propanoate 3-H3), 0.86 (3 H, t, J = 7.1 Hz, heptyl 7-H3); 13C NMR (125.77 
MHz, CDCl3): δC 173.9, 111.3, 65.5, 65.4, 51.7, 46.7, 35.0, 31.7, 29.7, 29.2, 22.8, 
22.6, 14.0, 12.5; ESI-MS m/z 281.1761 [M + Na]+ (C14H26NaO4 requires 
281.1729), 259.1883 [M + H]+ (C14H27O4 requires 259.1909). 
 
2-(2-Heptyl-1,3-dioxolan-2-yl)propanoic acid (38) 
Aq. NaOH (1.0 M, 6.7 mL, 6.7 mmol) was stirred with 36 (345 mg, 1.34 mmol) in 
MeOH (30 mL) at ambient temperature for 2 h, then at 65°C for 2 h. The mixture 
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was cooled to ambient temperature and citric acid buffer (0.8 M, pH 4.0, 15 mL) 
was added. The mixture was extracted with CH2Cl2 (3 × 30 mL). The combined 
organic layers were washed with water and brine and dried. Evaporation and 
column chromatography (petroleum ether / EtOAc 2:1) gave 38 (130 mg, 40 %) 
as a colourless oil. IR (neat) nmax 1709 (C=O) cm-1; 1H NMR (400.04 MHz, CDCl3): 
δH 10.78 (1 H, br s, OH), 4.10-3.94 (4 H, m, OCH2CH2O), 2.83 (1 H, q, J = 7.2 
Hz, CHCH3), 1.80-1.67 (2 H, m heptyl 1-H2), 1.43-1.20 (10 H, m, heptyl 2,3,4,5,6-
H10), 1.23 (3 H, d, J = 7.2 Hz, CHCH3), 0.87 (3 H, t, J = 7.1 Hz, heptyl 7-H3); 13C 
NMR (125.77 MHz, CDCl3): δC 176.9, 111.4, 65.4, 65.4, 46.6, 34.7, 31.7, 29.6, 
29.2, 22.8, 22.6, 14.0, 12.2; ESI-MS m/z 267.1549 [M + Na]+ (C13H24NaO4 
requires 267.1572),  245.1729 [M + H]+ (C13H25O4 requires 245.1753). 
 
2-(2-Heptyl-1,3-dioxolan-2-yl)propanoyl-CoA (24) 
Using the same method as for 21, 24 was prepared from 38 (31 mg, 0.13 mmol, 
1.0 eq.) by sequential treatment with N,N’-carbonyldiimidazole (41 mg, 0.25 
mmol, 2.0 eq.) and CoA-SH tri-lithium salt (29 mg, 0.04 mmol, 0.3 eq.) to give 24 
(10 mg) as a colourless solid: 1H NMR (500.13 MHz, D2O) δH 8.57 (1 H, s), 8.30 
(1 H, s), 6.13 (1 H, d, J = 6.1 Hz), 4.21-4.14 (1 H, m), 3.99-3.88 (4 H, m), 3.78 (1 
H, dd, J = 9.6, 4.5 Hz), 3.50 (1 H, dd, J = 9.7, 4.5 Hz), 3.39 (2 H, t, J = 6.6 Hz), 
3.32-3.22 (2 H, m), 3.12 (1 H, 2 x q, J = 7.0 Hz; both epimers), 2.93 (2 H, t, J = 
6.2 Hz), 2.36 (2 H, t, J = 6.6 Hz), 1.66-1.53 (2 H, m), 1.26-1.11 (8 H, m), 1.08 (3 
H, d, J = 7.0 Hz, CHCH3), 0.85 (3 H, s), 0.76 (3 H, t, J = 7.1 Hz, CH2CH3), 0.72 
(3 H, s); ESI-MS m/z 506.6219 [M + Na]2+ (C34H55N7NaO19P3S requires  
506.6192), 495.6301 [M + H]2+ (C34H56N7O19P3S requires 495.6282). 
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2R,S-2-Methyl-3-oxodecanoyl-CoA (25) 
Compound 24 (7 mg, 7.1 µmol) was dissolved in water (0.8 mL) and acetone (1.0 
mL). Aq. HCl (1.0 M, 0.2 mL) was added and the reaction mixture was stirred 
overnight. The acetone was evaporated and the residue freeze-dried to give 25 
(6 mg) as a colourless solid: 1H NMR (500.13 MHz, D2O): δH 8.49 (1 H, s), 8.33 
(1 H, s), 6.10 (1 H, d, J = 5.8 Hz), 4.20-4.10 (2 H, m), 3.99 (1 H, q, J = 7.0 Hz), 
3.76 (1 H, dd, J = 9.7, 5.0 Hz), 3.38-3.28 (2 H, m), 3.22 (2 H, t, J = 6.3 Hz), 2.97-
2.88 (2 H, m), 2.57-2.44 (2 H, m), 2.30 (2 H, t, J = 6.6 Hz), 1.41-1.32 (2 H, m), 
1.16 (3 H, d, J = 7.0 Hz), 1.12-1.04 (8 H, m), 0.80 (3 H, s), 0.69 (3 H, s), 0.68 (3 
H, t, J = 7.0 Hz); ESI-MS m/z 473.6174 [M – 2 H]2- (C32H52N7O18P3S requires 
473.6151). 
 
2S,3R-3-Hydroxy-2-methyldecanoyl-CoA (26) 
2S,3R-3-Hydroxy-2-methyldecanoic acid 39 was synthesised [48] from the 
Evan’s auxiliary protected acid 28 by hydrolysis with NaOH and H2O2. Following 
the procedure used for 21, 2S,3R-3-hydroxy-2-methyldecanoyl-CoA 26 was 
prepared from 2S,3R-3-hydroxy-2-methyldecanoic acid 39 (40 mg, 0.20 mmol, 
1.0 eq.), CDI (64 mg, 0.40 mmol, 2.0 eq.) and CoA-SH tri-lithium salt (78 mg, 0.10 
mmol, 0.5 eq.) to give 26 (12 mg) as a colourless solid: 1H NMR (500.13 MHz, 
D2O) δH 8.48 (1 H, s), 8.20 (1 H, s), 6.09 (1 H, d, J = 6.5 Hz), 4.22-4.10 (1 H, m), 
3.81-3.70 (1 H, m), 3.48 (1 H, dd, J = 9.8, 4.8 Hz), 3.37 (2 H, t, J = 6.6 Hz), 3.25 
(2 H, t, J = 6.3 Hz), 2.97-2.87 (2 H, m), 2.74-2.68 (1 H, m), 2.34 (2 H, t, J = 6.5 
Hz), 1.39-1.29 (2 H, m), 1.21-1.09 (10 H, m), 1.06 (3 H, d, J = 6.9 Hz, CHCH3), 
0.81 (3 H, s), 0.74 (3 H, t, J = 7.1 Hz, CH2CH3), 0.68 (3 H, s); ESI-MS m/z [M – 2 
H]2- 474.6217 (C32H54N7O18P3S requires 474.6229). 
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Evaluation of inhibition of AMACR by test compounds 
Colorimetric assays were performed as previously described [32]. Dose response 
curves were used to determine IC50 values for inhibitors. Enzyme (4 x stock, 150 
µL) and inhibitor at the appropriate concentration (4 x stock, 150 µL) were 
incubated together in 96 well plates at ambient room temperature for 10 min. The 
sample was divided into three repeats of 100 µL before addition of substrate (2 x 
stock, 3 x 100 µL; final concentration of 40 μM in the assay) and monitored at 
354 nm. Each 200 µL assay contained ca. 8 µg of total AMACR protein (0.85 µM, 
assuming a molecular weight of 47,146.8 Da. with one active site per monomer 
[7]). Final concentrations of inhibitor in the assay were 100, 33.3, 11.1, 3.7, 1.23, 
0.411, 0.137 and 0.045 µM unless otherwise stated. Positive controls contained 
enzyme and substrate 1 only and negative controls buffer and substrate. Rates 
in ΔAbsorbance.min-1 were determined using Excel and converted to nmol.min.-
1mg-1 using the 2,4-dinitrophenoxide 2 extinction coefficient (15,300 M-1 cm-1) [32] 
with the path-length (0.588 cm) determined by the plate-reader. IC50 values were 
determined using reaction rate, with the data fitted to a 4-parameter logistic using 
SigmaPlot 13 using Log10 inhibitor concentration (in μM). In some cases 2-3% 
(v/v) DMSO was included in assays; no significant change in enzyme activity was 
observed with DMSO concentrations of up to 8% (v/v) [32]. Half-volume 96 well 
plates were used for some inhibitors; identical IC50 values were obtained for 
standard inhibitors using both types of microtitre plate. IC50 values [32] for N-
dodecyl-N-methylcarbamoyl-CoA 4 and ibuprofenoyl-CoA 5 were determined 
contemporaneously with the inhibitors described in this study, with the same 
batch of enzyme. 
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Computational analysis of potency of inhibition 
Lipophilicity of acyl-CoA esters was assessed by calculation of miLogP values 
using the molecular properties calculator (http://www.molinspiration.com/cgi-
bin/properties). miLogP values were calculated using molecular smiles obtained 
from Chemdraw Professional 15. IC50 values (in nM) were plotted against the 
obtained LogP value using SigmaPlot 13.  
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Compound IC50 (nM) miLogP* Previously tested as 
substrate? 
Previously tested as 
Inhibitor? 
4 ~0.4 -2.61 No Yes [29, 32] 
5 540 -4.18 Yes [6, 29, 49] Yes [28, 32, 37, 38] 
6 400 -3.77 Yes [6, 11] Not tested 
7 590 -3.62 Yes [6] Not tested 
8 560 -4.07 Yes [6] Not tested 
9 750 -4.25 Yes [6] Not tested 
10 3.8 x 103 -5.46 Not a substrate [11] Not tested 
11 2.3 x 103 -5.46 Not a substrate [11] Not tested 
12 3.1 x 103 -3.63 Yes [36] Not tested 
13 9.6 x 103 -4.50 Yes [36] Yes – No inhibition [37, 38] 
14 1.6 x 104 -4.98 Yes [36] Not tested 
15 >1.0 x 105 -5.30 Poor substrate [36] Yes – No inhibition [37, 38] 
16 >1.0 x 105 -5.38 Not a substrate [36] Yes – No inhibition [37, 38] 
17 >1.0 x 105 -5.55 Not tested Yes – No inhibition [37, 38] 
18 930 -3.39 Yes [7] Not tested 
19 1170 -3.39 Yes [7, 36] Not tested 
20 200 -3.61 Yes [10] Not tested† 
21 300 -3.61 Not tested Not tested† 
22 180 -3.34 Not a substrate [10] Yes – No inhibition [37, 38] 
23 600 -3.56 Not tested Not tested‡ 
24 4.1 x 103 -4.02 Not tested Not tested 
25 360 -4.55 Not tested Not tested‖ 
26 560 -4.43 Not tested Not tested 
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Legends 
Scheme 1. The colorimetric assay for AMACR 1A [32] showing elimination of 
2,4-dinitrophenolate 2. 
 
Scheme 2.  Synthesis of (2S,3S)-3-fluoro-2-methyldecanoyl-CoA 21. Reagents 
and conditions: i. Bu2BOTf, Pri2NEt, octanal, CH2Cl2, -78°C, 76%; ii. DAST, 
CH2Cl2, -78°C, 35%; iii. LiOH, H2O2, H2O/THF, 0°C, 92%; iv. CDI, CH2Cl2, rt; v. 
CoA-SH Li+3, 0.1 M NaHCO3 aq. /THF (1:1). 
 
Scheme 3. Synthesis of 2-methylenedecanoyl-CoA 23. Reagents and conditions: 
i, DCC, DMAP, CH2Cl2; ii, NaBH4, AcOH, 89% over two steps; iii, Me2N+=CH2 I-, 
MeOH, 74%; iv, NaOH, EtOH, 80%; v, NEt3, EtOCOCl, THF; vi, aq. KHCO3 (2.5% 
w/v), CoA-SH Li+3, THF. 
 
Scheme 4. Synthesis of 2-methyl-3-oxodecanoyl-CoA 25. Reagents and 
conditions: i, ethane-1,2-diol, TMSCl, CH2Cl2, 82%; ii, aq. NaOH / MeOH, 40%; 
iii, CDI, CH2Cl2; v, CoA-SH Li+3, 0.1 M NaHCO3 aq. /THF (1:1); iv, aq. HCl, acetone. 
 
Scheme 5:  Synthesis of (2S,3R)-3-hydroxy-2-methyldecanoyl-CoA 26. 
Reagents and conditions: i. NaOH, H2O2, rt, quant.; ii. CDI, CH2Cl2, rt; iii. CoA-
SH Li+3, 0.1 M NaHCO3 aq. /THF (1:1). 
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Figure 1. Structures for AMACR inhibitors, as measured by the colorimetric 
assay [32]. *Calculated miLogP values are for the acyl-CoA ester 
(http://www.molinspiration.com/cgi-bin/properties). †(2R,3R)- and (2S,3S)-3-
Fluoro-2-methylhexadecanoyl-CoA were previously shown to be AMACR 
inhibitors [28]. ‡Several side-chain analogues of 23 reported as inhibitors [30]. 
‖Binding of the 2-methylacetoacetyl-CoA enolate to MCR observed by X-ray 
crystallography [9]. 
 
Figure 2. Incubation of 2S,3R-3-hydroxy-2-methyldecanoyl-CoA 26 with AMACR 
in buffer and 2H2O. A. Heat-inactivated enzyme; B. live enzyme. Red circles 
highlight doublet for substrate 2-methyl group, showing no exchange of the α-
proton had occurred (conversion to a single peak occurs on exchange to α-2H 
upon ‘racemisation’ [7, 11]). Green circles denote expected position of 2-methyl 
singlet for the expected unsaturated product 22, showing that no elimination 
reaction has occurred. 
 
Figure 3. Correlation of inhibitor potency with lipophilicity (miLogP value; 
http://www.molinspiration.com/cgi-bin/properties). Compound numbers refer to 
structures shown in Figure 1. Compounds with green numbers are those with 
aromatic side-chains (5 – 11); Compounds with blue numbers are straight-chain 
acyl-CoA esters and iso-butanoyl-CoA (12 – 17); Compounds with purple 
numbers are 2-methyldecanoyl-CoA and 3-fluoro-2-methyldecanoyl-CoAs (18 - 
21); Compounds with orange numbers are intermediates in the β-oxidation 
pathway which occurs subsequent to AMACR activity (22, 25 and 26); 
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Compounds with red numbers are inhibitors or analogues of known inhibitors (4 
and 23); Compound 24 is a synthetic intermediate to 25. 
 
 
 
